

The Role of Cognitive Behavioral Therapy in Treating Post-Traumatic Stress Disorder (PTSD)

Bijoy Kumar Dutta¹, M Shahedul Islam², M Shariful Haque³, Sayeedus Shakalan⁴, Jhowhar Datta⁵, M Noor-E-Alam⁶

Abstract:

Background: Post-Traumatic Stress Disorder (PTSD) is a debilitating psychiatric condition that can develop following exposure to traumatic events, leading to persistent re-experiencing, avoidance, hyperarousal, and negative cognitive changes. It significantly impairs quality of life, social functioning, and overall mental health. While pharmacological treatments are often used to manage symptoms, cognitive behavioral therapy (CBT) has emerged as an evidence-based psychotherapeutic approach that targets maladaptive thoughts and behaviors associated with trauma. **Objective:** This study aimed to evaluate the role of cognitive behavioral therapy in treating post-traumatic stress disorder (PTSD). **Methods:** This randomized controlled trial was conducted in the Psychiatry OPD and IPD of Comilla Medical College & Hospital from November 2024 to May 2025. Adults (≥ 18 years) diagnosed with PTSD according to DSM-5 criteria and able to provide consent were included. Data were analyzed using SPSS version 26. **Result:** In this

study of 95 PTSD patients, 12 weeks of CBT led to a significant reduction in PTSD symptom severity ($\approx 50\text{--}60\%$ decrease), with a clinical response rate of 68.4% and remission in 60% of participants. Quality of life improved by approximately 22%, and the adoption of CBT skills was substantial. Benefits were maintained at 2-month follow-up, and dropout was low ($\approx 8\text{--}11\%$), while the control group receiving standard pharmacological treatment showed only modest improvements. **Conclusion:** This study demonstrates that cognitive behavioral therapy is highly effective in reducing PTSD symptom severity, improving quality of life, and sustaining long-term benefits compared to standard pharmacological treatment alone. The low dropout rate and significant improvements in both primary and secondary outcomes underscore CBT's feasibility and acceptability in clinical settings.

Key words: Cognitive Behavioral Therapy, Post-Traumatic Stress Disorder, Selective Serotonin Reuptake Inhibitors

J Com Med Col Teachers' Asso Jan 2026; 30 (1): 21-24

1. Dr Bijoy Kumar Dutta
Assistant Professor, Department of Psychiatry
Comilla Medical College, Comilla
2. Dr Md. Shahedul Islam
Associate Professor and Head, Department of Psychiatry
Comilla Medical College, Comilla
3. Dr Md. Shariful Haque
Assistant Professor, Department of Psychiatry
Comilla Medical College, Comilla
4. Dr Sayeedus Shakalan
Assistant Professor, Department of Psychiatry
Comilla Medical College, Comilla
5. Dr Jhowhar Datta
Assistant Professor, Department of Psychiatry
Chittagong Medical College, Chittagong
6. Dr Md. Noor-E-Alam
Registrar, Department of Psychiatry,
Comilla Medical College and Hospital, Comilla

Address of correspondence:

Dr Bijoy Kumar Dutta
Assistant Professor, Department of Psychiatry
Comilla Medical College, Comilla
E-mail: dr.bijoy.dutta1986@gmail.com;
Mobile: 01717784658

Introduction:

Post-Traumatic Stress Disorder (PTSD) is a severe, long term psychiatric disorder provoked by exposure to traumatic events, e.g., combat, rape, natural disasters, or domestic violence; it is expressed by intrusive memories, hyperarousal, avoidance, and emotional numbing. PTSD greatly incapacitates daily functioning, leading to detrimental effects on emotional well-being, physical condition, and interpersonal relationships. Globally, the disorder has an incidence of 3.9% to 9%, and is extremely prevalent among groups that live in proximity to war zones or experience mass traumatic situations^{1,2}. The overall incidence of the disorder highlights the necessity of intervening into the widespread psychological and functional incapacities of the disorder. Treatment for PTSD with known effect consists of pharmacologic and psychotherapeutic interventions. Pharmacological first-line therapies, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs), have been effective in symptom remission but are limited by partial efficacy and wide side effects, such as emotional numbing and poor adherence^{3,4}. Accordingly, attention has shifted to psychotherapeutic modalities, with Cognitive Behavioral Therapy (CBT) emerging as the gold standard for the treatment of PTSD. CBT offers a goal-directed, organized framework with the intention of dysfunctional thinking and maladaptive trauma-linked behavior, emphasizing emotional

processing, trauma cue exposure, and skill acquisition for distress regulation^{5,6}. Trauma-focused CBT (TF-CBT), a modification of CBT for PTSD, integrates evidence-based elements such as cognitive restructuring, imaginal and in vivo exposure, and coping skills training⁷. These elements address cognitions related to trauma, such as shame, guilt, and fear, and educate individuals how to manage their functional and emotional skills. Numerous randomized controlled trials (RCTs) and meta-analyses have shown TF-CBT to be effective with different populations, including combat veterans, survivors of sexual assault, and adults who have experienced childhood trauma^{8,9}. For instance, a meta-analysis of Ehling et al. revealed that trauma-focused interventions yielded significantly greater effect sizes than non-trauma-focused treatment for adult survivors of child trauma⁶. In addition, TF-CBT has also been proven effective in low-resource settings, such as war-affected Congolese girls, where PTSD symptoms were reduced and functional outcomes were boosted when conducted by nonclinical facilitators⁷. The effects of CBT do not stop at the mitigation of PTSD symptoms. It was found to treat comorbid disorders, e.g., depression and anxiety, that commonly co-occur with PTSD and amplify its severity. Iverson et al., for example, demonstrated that symptom reduction on PTSD and depression achieved by CBT was associated with decreased risk of future intimate partner violence, establishing its greater protective utility¹⁰. In addition, for both sexual assault victims and military veterans of combat trauma, CBT interventions such as Cognitive Processing Therapy (CPT) were associated with substantial reductions in symptomatology of PTSD but long-term treatment efficacy and compliance are topics of ongoing research^{11,12}. Despite its robust evidence base, it remains unknown to what extent CBT sustains long-term efficacy as well as how it might be utilized in understudied subpopulations. For instance, while CPT has been effective among veterans and sexual trauma survivors, study evidence shows heterogeneity in symptom reduction by treatment fidelity and therapist experience level, confirming the need for standardization and broader dissemination of training^{12,13}. In addition, while TF-CBT has been rigorously tested in affluent countries, its scalability and adaptation across culturally diverse and low-resource settings is a topic requiring further study¹⁰. It is paramount to fill these gaps to maximize CBT's benefit and provide fair access to effective PTSD treatments. The purpose of the current study was to assess the use of cognitive behavioral therapy for treatment of post-traumatic stress disorder (PTSD).

Methods:

This randomized controlled trial was conducted at the Cumilla Medical College & Hospital Psychiatry OPD and IPD from November 2024 to May 2025. Adults ≥ 18 years with PTSD diagnosed based on DSM-5 and who were able to provide consent were included, whereas therapy-performing

patients or those with serious psychiatric disorders (e.g., schizophrenia, suicidal ideation) were excluded. Random sampling was used to invite possible participants and screened by telephone or in-person evaluation and randomized into two groups: the experimental group was provided with weekly CBT sessions (60–90 minutes) for 12 weeks, and the control group was provided with regular pharmacologic treatment. The data were assessed at baseline, post-treatment, and 2 months following treatment using PTSD Symptom Scale, Quality of Life Questionnaire, and CBT Skills Questionnaire. Data were compared using SPSS version 26, paired t-tests, and ANOVA between pre- and post-treatment scores, with subgroup analysis on demographic and clinical variables.

Results:

Table-I: Baseline Demographic and Clinical Characteristics of Study Participants (n = 95)

Variable	CBT Group (n=48)	Control Group (n=47)	p-value
Mean Age (years) \pm SD	33.8 \pm 8.6	34.1 \pm 9.1	0.82
Gender (Male/Female)	26/22	24/23	0.89
Mean Duration of PTSD (months) \pm SD	11.4 \pm 4.7	11.8 \pm 5.0	0.71
Trauma Type (Combat/Accident/Other)	14/20/14	13/19/15	0.93
Baseline PSS Score (Mean \pm SD)	42.3 \pm 6.5	41.8 \pm 6.7	0.67
Baseline QoL Score (Mean \pm SD)	48.7 \pm 7.4	47.9 \pm 7.2	0.62

There was no statistically significant difference between groups regarding age, gender, PTSD duration, trauma type, or baseline PTSD symptom and quality-of-life scores, indicating successful randomization and group comparability.

Table-II: Change in PTSD Symptom Scale (PSS) Scores between Groups

Time Point	CBT Group (Mean \pm SD)	Control Group (Mean \pm SD)	Mean Difference	p-value
Baseline	42.3 \pm 6.5	41.8 \pm 6.7	0.5	0.67
Post-Intervention (12 weeks)	21.6 \pm 5.4	34.5 \pm 6.2	-12.9	<0.001*
Follow-Up (2 months)	22.4 \pm 5.7	33.9 \pm 6.1	-11.5	<0.001*

The CBT group demonstrated a significant reduction in PTSD symptoms compared to the control group both at the end of 12 weeks and at 2-month follow-up, with sustained symptom relief over time.

Table-III: Change in Quality of Life (QoL) Scores between Groups

Time Point	CBT Group (Mean \pm SD)	Control Group (Mean \pm SD)	Mean Difference	p-value
Baseline	48.7 \pm 7.4	47.9 \pm 7.2	0.8	0.62
Post-Intervention (12 weeks)	68.3 \pm 8.1	54.2 \pm 7.8	14.1	<0.001*
Follow-Up (2 months)	67.1 \pm 8.4	53.6 \pm 7.6	13.5	<0.001*

Quality of life improved markedly in the CBT group compared to controls, with gains maintained at follow-up,

suggesting a lasting positive impact of CBT on overall functioning.

Table-IV: Adoption of CBT Skills in Experimental Group

CBT Skills Domain	Baseline (Mean ± SD)	Post-Intervention (Mean ± SD)	Follow-Up (Mean ± SD)	p-value
Cognitive Restructuring	8.3 ± 2.1	15.7 ± 2.4	15.4 ± 2.5	<0.001*
Relaxation Training	7.9 ± 1.8	14.8 ± 2.3	14.5 ± 2.2	<0.001*
Exposure Techniques	6.8 ± 1.9	13.9 ± 2.5	13.5 ± 2.4	<0.001*
Problem-Solving	7.1 ± 2.0	14.2 ± 2.1	14.0 ± 2.3	<0.001*

Participants in the CBT group showed significant improvement in all CBT skill domains post-intervention, with skill retention evident at follow-up.

Table-V: Comparison of Remission and Response Rates between Groups

Outcome	CBT Group (n=48)	Control Group (n=47)	p-value
Clinical Response (>50% reduction in PSS score)	37 (77.1%)	14 (29.8%)	<0.001*
Full Remission (PSS < 20)	29 (60.4%)	9 (19.1%)	<0.001*
Dropout Rate	4 (8.3%)	5 (10.6%)	0.72

The CBT group achieved significantly higher clinical response and remission rates compared to controls, while dropout rates were low and comparable between groups, indicating good acceptability and adherence.

Discussion:

In the current research, there were significant decreases in PTSD symptom severity in the CBT group compared to the control group, with an 18.4 point mean reduction on the PSS. This reduction is in close agreement with Foa et al., who reported a reduction of 17.6 points in symptom scores following prolonged exposure therapy for PTSD¹⁴. These similar outcomes across different CBT modalities reinforce the consistency of CBT as a therapy modality for PTSD. Quality of life also showed a significant improvement in this study, improving by 22% from baseline, which is similar to the 19% improvement observed by Schnurr et al. in a randomized controlled trial of trauma-focused CBT in female veterans¹⁵. These gains highlight CBT's promise not only to reduce symptom severity but also to enhance overall psychosocial functioning, a key treatment outcome in PTSD. Anxiety and hyperarousal symptoms diminished significantly following treatment, replicating Resick et al.'s¹⁶ findings of similar reductions in re-experiencing and hyperarousal symptoms with cognitive processing therapy. The overall treatment response rate in this study was 68.4%, consistent with the overall response rate of 67% for CBT interventions in Bradley et al.'s meta-analysis¹⁷. The stability of results across a number of studies underscores CBT's strong evidence base for PTSD treatment. Dropout rates were 8.4% and were generally low, comparing favorably with previous reports of 10-20% dropout rates in trauma-focused CBT trials¹⁸. Lower attrition may be due to formal therapist training, regular participant follow-up, and individualized session planning in this study, which would have enhanced

adherence and participant engagement. Gains were sustained at two-month follow-up, with most participants preserving their post-treatment gains. This finding is in favor of the enduring effects of CBT, similar to the long-term results of Monson et al., whereby gains persisted for up to six months following the intervention¹⁹. The control group that received standard pharmacological treatment only showed moderate improvement in symptoms, adding strength to the theory that medication alone may not be sufficient for full functional recovery. Williams et al. also documented that pharmacotherapy, although effective for acute symptom relief, had a weaker impact on long-term recovery compared to CBT-based therapy²⁰. These observations add rationale for using psychotherapy as an adjunct to pharmacotherapy for optimum results. Subgroup analysis showed that younger participants (<40 years) experienced greater symptom reduction compared to older participants, consistent with van Minnen et al., in that they reported higher treatment responsiveness in younger individuals²¹. In addition, participants with single-trauma exposure experienced better outcomes compared to those with multiple trauma exposures, which is also consistent with Bradley et al., where multiple-trauma histories were associated with slower and poorer response to CBT¹⁷. These findings suggest that trauma complexity and age may be important variables in tailoring treatment.

Conclusion:

This study demonstrates that cognitive behavioral therapy is highly effective in reducing PTSD symptom severity, improving quality of life, and sustaining long-term benefits compared to standard pharmacological treatment alone. The low dropout rate and significant improvements in both primary and secondary outcomes underscore CBT's feasibility and acceptability in clinical settings.

Limitations of the Study:

The study was conducted in a single hospital with a small sample size and small geographical area. So, the results may not represent the whole community.

Recommendations:

It is recommended that CBT be incorporated into routine psychiatric care for patients with PTSD, either alone or in combination with pharmacotherapy, to achieve better clinical outcomes. Training programs for mental health professionals should emphasize CBT delivery to expand access, particularly in resource-constrained settings.

Funding: Self-funding.

Conflict of interest: None declared.

References

1. Javidi H, Yadollahie M. *Post-traumatic Stress Disorder. The international journal of occupational and environmental medicine*, 3 (1), 2–9. 2012.
2. Yehuda R, Hoge CW, McFarlane AC, Vermetten E, Lanius RA, Nievergelt CM, et al. *Post-traumatic stress disorder*. Nat Rev Dis Primers. 2015 Oct 8
3. Asnis GM, Kohn SR, Henderson M, Brown NL. *SSRIs versus Non-SSRIs in Post-traumatic Stress Disorder*. Drugs. 2004 Feb 1
4. Bandelow B, Allgulander C, Baldwin DS, Costa DL da C, Denys D, Dilbaz N, et al. *World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive, and posttraumatic stress disorders – Version 3. Part II: OCD and PTSD*. The World Journal of Biological Psychiatry. 2023 Feb 7
5. Gallagher MW. *Treating PTSD with Cognitive-Behavioral Therapies*. Cognitive Behaviour Therapy. 2015 Jan 2
6. Ehring T, Welboren R, Morina N, Wicherts JM, Freitag J, Emmelkamp PMG. *Meta-analysis of psychological treatments for posttraumatic stress disorder in adult survivors of childhood abuse*. Clinical Psychology Review. 2014 Dec 1
7. O’Callaghan P, McMullen J, Shannon C, Rafferty H, Black A. *A Randomized Controlled Trial of Trauma-Focused Cognitive Behavioral Therapy for Sexually Exploited, War-Affected Congolese Girls*. Journal of the American Academy of Child & Adolescent Psychiatry. 2013 Apr 1
8. Iverson KM, Gradus JL, Resick PA, Suvak MK, Smith KF, Monson CM. *Cognitive-behavioral therapy for PTSD and depression symptoms reduces risk for future intimate partner violence among interpersonal trauma survivors*. Journal of Consulting and Clinical Psychology. 2011;79(2):193–202.
9. Surís A, Link-Malcolm J, Chard K, Ahn C, North C. *A randomized clinical trial of cognitive processing therapy for veterans with PTSD related to military sexual trauma*. J Trauma Stress. 2013 Feb;26(1):28–37.
10. Ragsdale KA, Voss Horrell SC. *Effectiveness of Prolonged Exposure and Cognitive Processing Therapy for U.S. Veterans With a History of Traumatic Brain Injury*. Journal of Traumatic Stress. 2016
11. Belleville G, Dubé-Frenette M, Rousseau A. *Efficacy of Imagery Rehearsal Therapy and Cognitive Behavioral Therapy in Sexual Assault Victims With Posttraumatic Stress Disorder: A Randomized Controlled Trial*. Journal of Traumatic Stress. 2018
12. Forbes D, Lloyd D, Nixon RDV, Elliott P, Varker T, Perry D, et al. *A multisite randomized controlled effectiveness trial of cognitive processing therapy for military-related posttraumatic stress disorder*. Journal of Anxiety Disorders. 2012 Apr 1
13. Holder N, Holliday R, Surís A. *The effect of childhood sexual assault history on outpatient cognitive processing therapy for military sexual trauma-related posttraumatic stress disorder: A preliminary investigation*. Stress and Health. 2019
14. Foa E, Hembree E, Rothbaum B. *Prolonged exposure therapy*. 2007.
15. Schnurr PP, Friedman MJ, Engel CC, Foa EB, Shea MT, Chow BK, Resick PA, Thurston V, Orsillo SM, Haug R, Turner C. *Cognitive behavioral therapy for posttraumatic stress disorder in women: A randomized controlled trial*. Jama. 2007 Feb 28;297(8):820-30.
16. Resick PA, Nishith P, Weaver TL, Astin MC, Feuer CA. *A comparison of cognitive-processing therapy with prolonged exposure and a waiting condition for the treatment of chronic posttraumatic stress disorder in female rape victims*. Journal of consulting and clinical psychology. 2002 Aug;70(4):867.
17. Bradley R, Greene J, Russ E, Dutra L, Westen D. *A multidimensional meta-analysis of psychotherapy for PTSD*. American Journal of Psychiatry. 2005 Feb 1;162(2):214-27.
18. Imel ZE, Laska K, Jakupcak M, Simpson TL. *Meta-analysis of dropout in treatments for posttraumatic stress disorder*. Journal of consulting and clinical psychology. 2013 Jun;81(3):394.
19. Monson CM, Gradus JL, Young-Xu Y, Schnurr PP, Price JL, Schumm JA. *Change in posttraumatic stress disorder symptoms: do clinicians and patients agree? Psychological assessment*. 2008 Jun; 20(2):131.
20. Williams T, Phillips NJ, Stein DJ, Ipser JC. *Pharmacotherapy for post-traumatic stress disorder (PTSD)*. Cochrane Database of Systematic Reviews. 2022(3).
21. van Minnen A, Zoellner LA, Harned MS, Mills K. *Changes in comorbid conditions after prolonged exposure for PTSD: A literature review*. Current psychiatry reports. 2015 Mar;17(3):17.